NO963911L - Innretning for behandling av autoimmune sykdommer og fremgangsmåte for behandling - Google Patents

Innretning for behandling av autoimmune sykdommer og fremgangsmåte for behandling

Info

Publication number
NO963911L
NO963911L NO963911A NO963911A NO963911L NO 963911 L NO963911 L NO 963911L NO 963911 A NO963911 A NO 963911A NO 963911 A NO963911 A NO 963911A NO 963911 L NO963911 L NO 963911L
Authority
NO
Norway
Prior art keywords
treatment
autoimmune diseases
methods
tbg
treatment methods
Prior art date
Application number
NO963911A
Other languages
English (en)
Other versions
NO963911D0 (no
Inventor
Ivan Nikolaevich Golovistikov
Leonid Yazonovich Kacharava
Jury Semyonovich Tatarinov
Khallar Abdumuslimov Alikhanov
Original Assignee
Ivan Nikolaevich Golovistikov
Leonid Yazonovich Kacharava
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivan Nikolaevich Golovistikov, Leonid Yazonovich Kacharava filed Critical Ivan Nikolaevich Golovistikov
Publication of NO963911D0 publication Critical patent/NO963911D0/no
Publication of NO963911L publication Critical patent/NO963911L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Trofoblast B-I-glykoprotein (TBG) ble anvendt som et middel for å behandle autoimmune sykdommer som viser suppressorimmunosvikt.En fremgangsmåte for behandling av autoimmune sykdommer omfatter administrering av et immunkorirgerende preparat, der preparatet er trofoblast B-I-glykoprotein (TBG), indikasjoner med hensyn på dette preparatet blir bestemt ved testing av TBG-sensitivitet av mononukleære celler (MNC).
NO963911A 1994-03-18 1996-09-18 Innretning for behandling av autoimmune sykdommer og fremgangsmåte for behandling NO963911L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU9494008169A RU2056852C1 (ru) 1994-03-18 1994-03-18 Средство для лечения аутоиммунных заболеваний с иммунодефицитом супрессоров и способ лечения аутоиммунных заболеваний
PCT/RU1995/000047 WO1995025531A1 (fr) 1994-03-18 1995-03-16 Agent therapeutique contre les maladies auto-immunes et mode de traitement

Publications (2)

Publication Number Publication Date
NO963911D0 NO963911D0 (no) 1996-09-18
NO963911L true NO963911L (no) 1996-11-08

Family

ID=20153349

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963911A NO963911L (no) 1994-03-18 1996-09-18 Innretning for behandling av autoimmune sykdommer og fremgangsmåte for behandling

Country Status (22)

Country Link
US (1) US6150326A (no)
EP (1) EP0790059B1 (no)
JP (1) JPH09510473A (no)
KR (1) KR100382252B1 (no)
CN (1) CN1146156A (no)
AT (1) ATE260111T1 (no)
AU (1) AU699896B2 (no)
BG (1) BG62759B1 (no)
CA (1) CA2185892A1 (no)
CZ (1) CZ285856B6 (no)
DE (2) DE69532611D1 (no)
ES (1) ES2107980T1 (no)
FI (1) FI963671A (no)
GE (1) GEP20012377B (no)
GR (1) GR980300023T1 (no)
HU (1) HUT75720A (no)
NO (1) NO963911L (no)
PL (1) PL179765B1 (no)
RU (1) RU2056852C1 (no)
SK (1) SK281948B6 (no)
UA (1) UA26939C2 (no)
WO (1) WO1995025531A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0030729D0 (en) * 2000-12-16 2001-01-31 Univ Nottingham Substituted-4-Quinolones
WO2004032867A2 (en) * 2002-10-09 2004-04-22 Tolerrx, Inc. Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
RU2303995C1 (ru) * 2006-04-28 2007-08-10 Халлар Абдумуслимович Алиханов Средство, обладающее иммунорегуляторным свойством и его применение для лечения аутоиммунных заболеваний

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2862449D1 (en) * 1977-08-22 1984-11-22 Nat Res Dev Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
JPS61186322A (ja) * 1985-02-13 1986-08-20 Nippon Univ 免疾調節剤
IT1188646B (it) * 1986-04-09 1988-01-20 Ellem Ind Farmaceutica Tripeptide ad attivita' immunostimolante
US4803072A (en) * 1986-09-10 1989-02-07 Smithkline Beckman Corporation Immunomodulation
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US5169835A (en) * 1989-01-18 1992-12-08 Oklahoma Medical Research Foundation Pregancy specific proteins applications
FR2650183A1 (fr) * 1989-07-25 1991-02-01 Pasteur Institut Proteines immunostimulantes, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et application de ces produits a des fins therapeutiques et de diagnostic
US5118669A (en) * 1989-09-20 1992-06-02 Hitachi Chemical Co., Ltd. Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators
US5559097A (en) * 1990-01-12 1996-09-24 Idaho Research Foundation, Inc. Use of a pregnancy specific protein as an immunosuppressive
RU1836957C (ru) * 1990-03-25 1993-08-30 2-й Московский государственный медицинский институт им.Н.И.Пирогова Способ получени трофобластического бета @ -гликопротеина
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease

Also Published As

Publication number Publication date
HUT75720A (en) 1997-05-28
GR980300023T1 (en) 1998-04-30
BG100921A (en) 1997-12-30
AU2087495A (en) 1995-10-09
PL316311A1 (en) 1997-01-06
US6150326A (en) 2000-11-21
WO1995025531A1 (fr) 1995-09-28
HU9602558D0 (en) 1996-11-28
CN1146156A (zh) 1997-03-26
EP0790059B1 (en) 2004-02-25
SK281948B6 (sk) 2001-09-11
KR100382252B1 (ko) 2003-07-07
CA2185892A1 (en) 1995-09-28
BG62759B1 (bg) 2000-07-31
EP0790059A1 (en) 1997-08-20
CZ285856B6 (cs) 1999-11-17
PL179765B1 (pl) 2000-10-31
SK118796A3 (en) 1997-06-04
ATE260111T1 (de) 2004-03-15
NO963911D0 (no) 1996-09-18
RU2056852C1 (ru) 1996-03-27
DE69532611D1 (de) 2004-04-01
AU699896B2 (en) 1998-12-17
CZ274796A3 (en) 1997-06-11
JPH09510473A (ja) 1997-10-21
DE790059T1 (de) 1998-03-12
FI963671A (fi) 1996-11-14
FI963671A0 (fi) 1996-09-17
UA26939C2 (uk) 1999-12-29
KR970701557A (ko) 1997-04-12
EP0790059A4 (en) 2000-11-02
GEP20012377B (en) 2001-03-25
ES2107980T1 (es) 1997-12-16

Similar Documents

Publication Publication Date Title
NO784386L (no) Fremgangsmaate til desodorering av slam, spesielt klarslam
ES8307899A1 (es) "un metodo para detectar sangre humana oculta en muestras de deposicion humana".
DK147988D0 (da) Hoereapparat, navnlig til anbringelse i oeret
NO873522L (no) Apparat til bruk til energileting.
DK144128C (da) Analogifremgangsmaade til fremstilling af imidazo(2,1-b)quinazolin-2-oner
DK0489984T3 (da) Fremgangsmåde til at styre behandlingen af fjerkræ, samt indretning til udøvelse af denne fremgangsmåde
NO871830D0 (no) Komposittelektroder, framgangsmaate for framstilling av disse samt apparat der elektrodene benyttes.
NO903449D0 (no) Fremgangsmaate for aa behandle underjordiske formasjoner.
DK188481A (da) Fremgangsmaade til fremstilling af et organisk platinkompleks
DK164973C (da) Undersoegelsesmetode til bestemmelse af 1,25-dihydroxy vitamin d og saet til brug ved denne metode
DK305578A (da) Fremgangsmaade til fremstilling af bicycliske thia-diaza-forbindelser isaer 1,3-diaza-cyclopent-2-eno(2,1-b) (1-thia-3-aza-cycloalkaner).
NO159543C (no) Spikerplate, samt framgangsmaate til dennes framstilling og apparat til gjennomfoering av framgangsmaaten.
ES507705A0 (es) Procedimiento de fabricacion de derivados de tetrahidro-5,67,7a 4h-tieno (3,2-c) piridinona-2 .
NO865034D0 (no) Fremgangsmaate til fremstilling av et justerings- og proevestandardelement og ved fremgangsmaaten fremstilt justerings- og proevestandardelement.
NO963911L (no) Innretning for behandling av autoimmune sykdommer og fremgangsmåte for behandling
NO883658D0 (no) Fremgangsmaate til ionisk etsing under lav polariseringsspenning ved tilfoersel av inert gass.
DK277281A (da) 6-hydrazonopyrido (2,1-b) quinazolin-11-oner salte isomere og tautomere deraf samt fremgangsmaade til deres fremstilling
ES502354A0 (es) Procedimiento para la obtencion de granulados de componentes quimicos del caucho.
WO2000015799A3 (en) Rna-associated proteins
ES522967A0 (es) Procedimiento para la obtencion de alquilen(cicloalquilen)-bis-heterociclil-biguanidas.
WO2000011171A3 (en) Human rna-associated proteins
FI844187A0 (fi) Foerfarande foer framstaellning av (1,3)oxazino(4,3-a)-isokinolinderivat.
GB9716812D0 (en) Memory test equipment with optimisation function
SU841127A1 (ru) Индукционна установка
NO872358D0 (no) Fremgangsmaate for 2,3-dihydro-1-(8-methyl-1,2,4-triazolo-(4,3-b)pyridazin-6-yl)-4(1h)-pyridinoner.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application